Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftolozane-tazobactam for Neutropenic Fever in Hematology Patients
NCT05061654Phase 4Withdrawn
- Sponsor
- Hamad Medical Corporation
- Start
- Aug 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ceftolozane + tazobactam in febrile neutropenia (FN), sponsored by Hamad Medical Corporation. Planned start Aug 2022; status: withdrawn.
02
Drugs
ceftolozane + tazobactam
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT05061654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05061654.